Treatment of inflammatory complications in common variable immunodeficiency (CVID): current concepts and future perspectives

References

• Cunningham-Rundles C. Common variable immune deficiency: dissection of the variable. Immunol Rev. 2019 Jan;287(1):145–161.
   PubMed Web of Science ®Google Scholar
• Ho HE, Cunningham-Rundles C. Non-infectious complications of common variable immunodeficiency: updated clinical spectrum, sequelae, and insights to pathogenesis. Front Immunol. 2020;11:149.
   PubMed Web of Science ®Google Scholar
• Fischer A, Provot J, Jais JP, et al. Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies. J Allergy Clin Immunol. 2017 Nov;140(5):1388–1393.e8.
   PubMed Web of Science ®Google Scholar
• Gathmann B, Mahlaoui N, Gérard L, et al. Clinical picture and treatment of 2212 patients with common variable immunodeficiency. J Allergy Clin Immunol. 2014 Jul;134(1):116–126.
   PubMed Web of Science ®Google Scholar
• Cabañero-Navalon MD, Garcia-Bustos V, Nuñez-Beltran M, et al. Current clinical spectrum of common variable immunodeficiency in Spain: the multicentric nationwide GTEM-SEMI-CVID registry. Front Immunol. 2022;13:1033666.
   PubMed Web of Science ®Google Scholar
• Westh L, Mogensen TH, Dalgaard LS, et al. Identification and characterization of a nationwide danish adult common variable immunodeficiency cohort. Scand J Immunol. 2017 Jun;85(6):450–461.
   PubMed Web of Science ®Google Scholar
• Bonilla FA, Barlan I, Chapel H, et al. International Consensus Document (ICON): common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2016 Jan;4(1):38–59.
   PubMed Web of Science ®Google Scholar
• Seidel MG, Kindle G, Gathmann B, et al. The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity. J Allergy Clin Immunol Pract. 2019 Jul;7(6):1763–1770.
   PubMed Web of Science ®Google Scholar
• de Valles-Ibáñez G, Esteve-Solé A, Piquer M, et al. Evaluating the genetics of common variable immunodeficiency: monogenetic model and beyond. Front Immunol. 2018;9:636.
   PubMed Web of Science ®Google Scholar
• Chapel H, Lucas M, Lee M, et al. Common variable immunodeficiency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2): 277–286.
   PubMed Web of Science ®Google Scholar
• Bates CA, Ellison MC, Lynch DA, et al. Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiency. J Allergy Clin Immunol. 2004 Aug;114(2):415–421.
   PubMed Web of Science ®Google Scholar
• Resnick ES, Moshier EL, Godbold JH, et al. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood. 2012 Feb 16;119(7):1650–1657. DOI:10.1182/blood-2011-09-377945
   PubMed Web of Science ®Google Scholar
• Hill AT, Thompson RA, Wallwork J, et al. Heart lung transplantation in a patient with end stage lung disease due to common variable immunodeficiency. Thorax. 1998 Jul;53(7):622–623.
   PubMed Web of Science ®Google Scholar
• Burton CM, Milman N, Andersen CB, et al. Common variable immune deficiency and lung transplantation. Scand J Infect Dis. 2007;39(4):362–367.
   PubMed Web of Science ®Google Scholar
• Jørgensen SF, Macpherson ME, Bjøro K, et al. Liver transplantation in patients with primary antibody deficiency. J Allergy Clin Immunol. 2017 May;139(5):1708–1710.e2.
   PubMed Web of Science ®Google Scholar
• Azzu V, Elias JE, Duckworth A, et al. Liver transplantation in adults with liver disease due to common variable immunodeficiency leads to early recurrent disease and poor outcome. Liver Transpl. 2018 Feb;24(2):171–181.
   PubMed Web of Science ®Google Scholar
• Ramlaul N, Ooi J, Jeffrey GP, et al. Liver transplantation in adults with liver disease due to common variable immunodeficiency leads to early recurrent disease and poor outcome. Liver Transpl. 2018 Nov;24(11):1622–1626.
   PubMed Web of Science ®Google Scholar
• Andersen IM, Reims HM, Grzyb K, et al. Long-term survival after liver transplantation in patients with common variable immunodeficiency. Liver Transpl. 2023 Mar 20. Online ahead of print.
   Google Scholar
• Wehr C, Gennery AR, Lindemans C, et al. Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency. J Allergy Clin Immunol. 2015 Apr;135(4):988–997.e6.
   PubMed Web of Science ®Google Scholar
• Albert MH, Sirait T, Eikema DJ, et al. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study. Blood. 2022 Oct 6;140(14):1635–1649.
   PubMed Web of Science ®Google Scholar
• Boursiquot JN, Gérard L, Malphettes M, et al. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. J Clin Immunol. 2013 Jan;33(1):84–95.
   PubMed Web of Science ®Google Scholar
• Maglione PJ, Ko HM, Beasley MB, et al. Tertiary lymphoid neogenesis is a component of pulmonary lymphoid hyperplasia in patients with common variable immunodeficiency [Original]. J Allergy Clin Immunol. 2014 Feb;133(2):535–542.
   PubMed Web of Science ®Google Scholar
• Unger S, Seidl M, van Schouwenburg P, et al. The T(H)1 phenotype of follicular helper T cells indicates an IFN-γ-associated immune dysregulation in patients with CD21low common variable immunodeficiency. J Allergy Clin Immunol. 2018 Feb;141(2):730–740.
   PubMed Web of Science ®Google Scholar
• Maglione PJ, Gyimesi G, Cols M, et al. BAFF-driven B cell hyperplasia underlies lung disease in common variable immunodeficiency. JCI Insight. 2019 Mar 7;4(5). DOI:10.1172/jci.insight.122728
   PubMed Web of Science ®Google Scholar
• van Stigt AC, Dik WA, Kamphuis LSJ, et al. What works when treating granulomatous disease in genetically undefined CVID? A systematic review. Front Immunol. 2020;11:606389.
   PubMed Web of Science ®Google Scholar
• Berbers RM, van der Wal MM, van Montfrans JM, et al. Chronically activated t-cells retain their inflammatory properties in common variable immunodeficiency. J Clin Immunol. 2021 Oct;41(7):1621–1632.
   PubMed Web of Science ®Google Scholar
• Warnatz K, Denz A, Drager R, et al. Severe deficiency of switched memory B cells (Cd27(+)igm(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood. 2002 Mar 1;99(5):1544–1551.
   PubMed Web of Science ®Google Scholar
• Berglund LJ, Wong SW, Fulcher DA. B-cell maturation defects in common variable immunodeficiency and association with clinical features. Pathology. 2008 Apr;40(3):288–294.
   PubMed Web of Science ®Google Scholar
• Wehr C, Kivioja T, Schmitt C, et al. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood. 2008 Jan 1;111(1):77–85. DOI:10.1182/blood-2007-06-091744
   PubMed Web of Science ®Google Scholar
• Reincke ME, Payne KJ, Harder I, et al. The antigen presenting potential of CD21(low) B Cells. Front Immunol. 2020;11:535784.
   PubMed Web of Science ®Google Scholar
• Gobert D, Bussel JB, Cunningham-Rundles C, et al. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients. Br J Haematol. 2011 Nov;155(4):498–508.
   PubMed Web of Science ®Google Scholar
• Ng J, Wright K, Alvarez M, et al. Rituximab monotherapy for common variable immune deficiency-associated granulomatous-lymphocytic interstitial lung disease [Case reports]. Chest. 2019 May;155(5):e117–121.
   PubMed Web of Science ®Google Scholar
• Verbsky JW, Hintermeyer MK, Simpson PM, et al. Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency. J Allergy Clin Immunol. 2021 Feb;147(2):704–712.e17.
   PubMed Web of Science ®Google Scholar
• Knight T, Ravindranath Y, Callaghan MU. Successful treatment of an adolescent male with severe refractory evans syndrome using bortezomib-based therapy. J Pediatr Hematol Oncol. 2020 Mar;42(2):e110–113.
   PubMed Web of Science ®Google Scholar
• Sigmon L, Greene K, Hansen JJ. IV cyclosporine to treat refractory CVID enteropathy. Scand J Gastroenterol. 2012 Nov;47(11):1396–1397.
   PubMed Web of Science ®Google Scholar
• Deenick EK, Morey A, Danta M, et al. Reversible suppression of lymphoproliferation and thrombocytopenia with rapamycin in a patient with common variable immunodeficiency. J Clin Immunol. 2018 Feb;38(2):159–162.
   PubMed Web of Science ®Google Scholar
• Deyà-Martínez A, Esteve-Solé A, Vélez-Tirado N, et al. Sirolimus as an alternative treatment in patients with granulomatous-lymphocytic lung disease and humoral immunodeficiency with impaired regulatory T cells. Pediatr Allergy Immunol. 2018 Jun;29(4):425–432.
   PubMed Web of Science ®Google Scholar
• von Spee-Mayer C, Echternach C, Agarwal P, et al. Abatacept use is associated with steroid dose reduction and improvement in fatigue and CD4-Dysregulation in CVID Patients with Interstitial Lung Disease. J Allergy Clin Immunol Pract. 2021 Feb;9(2):760–770.e10.
   PubMed Web of Science ®Google Scholar
• Bonnet F, Morlat P, Viallard JF, et al. Pulmonary granuloma, polyarthritis and antiphospholipids in common variable immunodeficiency: resolution after IVIG and the role of immunoglobulin a. Clin Exp Rheumatol. 2005 May;23(3):428–429.
   PubMed Web of Science ®Google Scholar
• Thatayatikom A, Thatayatikom S, White AJ. Infliximab treatment for severe granulomatous disease in common variable immunodeficiency: a case report and review of the literature. Annals of allergy, asthma & immunology: official publication of the American College of Allergy. Asthma, & Immunology. 2005 Sep;95(3):293–300.
   PubMed Web of Science ®Google Scholar
• Chase NM, Verbsky JW, Hintermeyer MK, et al. Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID). J Clin Immunol. 2013 Jan;33(1):30–39.
   PubMed Web of Science ®Google Scholar
• Franxman TJ, Howe LE, Baker JR Jr. Infliximab for treatment of granulomatous disease in patients with common variable immunodeficiency. J Clin Immunol. 2014 Oct;34(7):820–827.
   PubMed Web of Science ®Google Scholar
• Kralickova P, Milota T, Litzman J, et al. CVID-Associated tumors: czech nationwide study focused on epidemiology, immunology, and genetic background in a cohort of patients with CVID. Front Immunol. 2018;9:3135.
   PubMed Web of Science ®Google Scholar
• Mayor PC, Eng KH, Singel KL, et al. Cancer in primary immunodeficiency diseases: cancer incidence in the United States Immune Deficiency Network Registry. J Allergy Clin Immunol. 2018 Mar;141(3):1028–1035.
   PubMed Web of Science ®Google Scholar
• von Spee-Mayer C, Koemm V, Wehr C, et al. Evaluating laboratory criteria for combined immunodeficiency in adult patients diagnosed with common variable immunodeficiency. Clin Immunol. 2019 Jun;203:59–62.
   PubMed Web of Science ®Google Scholar
• Yakaboski E, Fuleihan RL, Sullivan KE, et al. Lymphoproliferative Disease in CVID: a Report of Types and Frequencies from a US Patient Registry. J Clin Immunol. 2020 Apr;40(3):524–530.
   PubMed Web of Science ®Google Scholar
• Smith T, Cunningham-Rundles C. Lymphoid malignancy in common variable immunodeficiency in a single-center cohort. Eur J Haematol. 2021 Nov;107(5):503–516.
   PubMed Web of Science ®Google Scholar
• Oksenhendler E, Gérard L, Fieschi C, et al. Infections in 252 patients with common variable immunodeficiency. Clin Infect Dis. 2008 May 15;46(10):1547–1554.
   PubMed Web of Science ®Google Scholar
• Nguyen JT, Green A, Wilson MR, et al. Neurologic complications of common variable immunodeficiency. J Clin Immunol. 2016 Nov;36(8):793–800.
   PubMed Web of Science ®Google Scholar
• van de Ven A, Mader I, Wolff D, et al. Structural noninfectious manifestations of the central nervous system in common variable immunodeficiency disorders. J Allergy Clin Immunol Pract. 2020 Mar;8(3):1047–1062.e6.
   PubMed Web of Science ®Google Scholar
• Mormile I, Punziano A, Riolo CA, et al. Common variable immunodeficiency and autoimmune diseases: a retrospective study of 95 adult patients in a single tertiary care center. Front Immunol. 2021;12:652487.
   PubMed Web of Science ®Google Scholar
• Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018 Mar 15;131(11):1172–1182.
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C. Common variable immune deficiency: case studies. Blood. 2019 Nov 21;134(21):1787–1795.
   PubMed Web of Science ®Google Scholar
• Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019 Dec 10;3(23):3829–3866.
   PubMed Web of Science ®Google Scholar
• Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the first international consensus meeting. Blood Rev. 2020 May;41:100648.
   PubMed Web of Science ®Google Scholar
• Chawla S, Barman P, Tyagi R, et al. Autoimmune cytopenias in common variable immunodeficiency are a diagnostic and therapeutic conundrum: an update. Front Immunol. 2022;13:869466.
   PubMed Web of Science ®Google Scholar
• Wong GK, Goldacker S, Winterhalter C, et al. Outcomes of splenectomy in patients with common variable immunodeficiency (CVID): a survey of 45 patients. Clin Exp Immunol. 2013 Apr;172(1):63–72.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010 Mar;37(3):558–567.
   PubMed Web of Science ®Google Scholar
• Barmettler S, Ong MS, Farmer JR, et al. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018 Nov 2;1(7):e184169.
   PubMed Web of Science ®Google Scholar
• Ghanima W, Cooper N, Rodeghiero F, et al. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019 Jun;104(6):1112–1123.
   PubMed Web of Science ®Google Scholar
• Carrabba M, Barcellini W, Fabio G. Use of thrombopoietin-receptor agonist in CVID-Associated immune thrombocytopenia. J Clin Immunol. 2016 Jul;36(5):434–436.
   PubMed Web of Science ®Google Scholar
• Citrin R, Foster JB, Teachey DT. The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders. Expert Rev Hematol. 2016 Sep;9(9):873–889.
   PubMed Web of Science ®Google Scholar
• Turnbull MT, Siegel JL, Becker TL, et al. Early bortezomib therapy for refractory Anti-NMDA receptor encephalitis. Front Neurol. 2020;11:188.
   PubMed Web of Science ®Google Scholar
• Schwarz L, Akbari N, Prüss H, et al. Clinical characteristics, treatments, outcome, and prognostic factors of severe autoimmune encephalitis in the intensive care unit: standard treatment and the value of additional plasma cell-depleting escalation therapies for treatment-refractory patients. Eur J Neurol. 2023; 30(2): 474–489.
   PubMed Web of Science ®Google Scholar
• Scheuerlein P, Pietsch L, Camacho-Ordonez N, et al. Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia? Front Immunol. 2018;9:1656.
   PubMed Web of Science ®Google Scholar
• Jørgensen SF, Reims HM, Frydenlund D, et al. A cross-sectional study of the prevalence of gastrointestinal symptoms and pathology in patients with common variable immunodeficiency. Am J Gastroenterol. 2016 Oct;111(10):1467–1475.
   PubMed Web of Science ®Google Scholar
• Strohmeier V, Andrieux G, Unger S, et al. Interferon-driven immune dysregulation in common variable immunodeficiency-associated villous atrophy and norovirus infection. J Clin Immunol. 2023;43(2): 371–390 .
   PubMed Web of Science ®Google Scholar
• van Schewick CM, Lowe DM, Burns SO, et al. Bowel histology of CVID patients reveals distinct patterns of mucosal inflammation. J Clin Immunol. 2022 Jan;42(1):46–59.
   PubMed Web of Science ®Google Scholar
• Kaarbø M, Yang M, Hov JR, et al. Duodenal inflammation in Common variable immunodeficiency has altered transcriptional response to viruses. J Allergy Clin Immunol 2023;151(3):767–777 .
   PubMed Web of Science ®Google Scholar
• Chua I, Standish R, Lear S, et al. Anti-tumour necrosis factor-alpha therapy for severe enteropathy in patients with common variable immunodeficiency (CVID). Clin Exp Immunol. 2007 Nov;150(2):306–311.
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C. How I treat common variable immune deficiency. Blood. 2010 Jul 8;116(1):7–15.
   PubMed Web of Science ®Google Scholar
• Prieto Elordui J, Arreba Gonzalez P, Ortiz de Zarate Sagastagoitia J, et al. Infliximab as treatment of severe enteropathy in a patient with common variable immunodeficiency and cytomegalovirus infection. Gastroenterol Hepatol. 2018 Mar;41(3):163–164.
   PubMed Web of Science ®Google Scholar
• Sifers T, Hirten R, Mehandru S, et al. Vedolizumab therapy in common variable immune deficiency associated enteropathy: a case series. Clin Immunol. 2020 Mar;212:108362.
   PubMed Web of Science ®Google Scholar
• Johnson D, Lee G, Weber F. Vedolizumab therapy in refractory enteropathy associated with CVID. ACG Case Rep J. 2022 Jan;9(1):e00721.
   PubMed Web of Science ®Google Scholar
• Ruiz de Morales JG, Muñoz F, Hernando M. Successful treatment of common variable immunodeficiency-associated inflammatory bowel disease with ustekinumab. J Crohns Colitis. 2017 Sep 1;11(9):1154–1155.
   PubMed Web of Science ®Google Scholar
• Straatmijer T, van Schaik FDM, Bodelier AGL, et al. Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC Registry. Aliment Pharmacol Ther. 2023;57(1): 117–126 .
   PubMed Web of Science ®Google Scholar
• Malamut G, Ziol M, Suarez F, et al. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J Hepatol. 2008 Jan;48(1):74–82.
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Friend J, Yang Z, et al. Nodular regenerative hyperplasia in common variable immunodeficiency. J Clin Immunol. 2013 May;33(4):748–758.
   PubMed Web of Science ®Google Scholar
• Azzu V, Fonseca M, Duckworth A, et al. Liver disease is common in patients with common variable immunodeficiency and predicts mortality in the presence of cirrhosis or portal hypertension. J Allergy Clin Immunol Pract. 2019 Sep;7(7):2484–2486.e3.
   PubMed Web of Science ®Google Scholar
• Crescenzi L, Pecoraro A, Fiorentino A, et al. Liver stiffness assessment by transient elastography suggests high prevalence of liver involvement in common variable immunodeficiency. Dig Liver Dis. 2019 Nov;51(11):1599–1603.
   PubMedGoogle Scholar
• Crotty R, Taylor MS, Farmer JR, et al. Spectrum of hepatic manifestations of common variable immunodeficiency. Am J Surg Pathol. 2020 May;44(5):617–625.
   PubMed Web of Science ®Google Scholar
• Apostolov R, Sinclair M, Lokan J, et al. Successful liver transplantation in common variable immune deficiency with reversal of hepatopulmonary syndrome. BMJ Case Rep. 2019 Apr 3;12(4):e226095.
   PubMedGoogle Scholar
• De Gottardi A, Sempoux C, Berzigotti A. Porto-sinusoidal vascular disorder. J Hepatol. 2022 Oct;77(4):1124–1135.
   PubMed Web of Science ®Google Scholar
• Kounis I, Sebagh M, Evain M, et al. Nodular regenerative hyperplasia is not a rare condition after liver transplantation: incidence, predictive factors, and impact on survival. Transplantation. 2023;107(2): 410–419 .
   PubMed Web of Science ®Google Scholar
• Sousa eSilva R, Pereira da Silva S, Luís R, et al. Nodular regenerative hyperplasia in CVID patients: could low-dose oral glucocorticoids be part of the solution? Eur Ann Allergy Clin Immunol. 2022 Mar 18. Online ahead of print.
   Google Scholar
• Mouillot G, Carmagnat M, Gérard L, et al. B-cell and T-cell phenotypes in CVID patients correlate with the clinical phenotype of the disease. J Clin Immunol. 2010 Sep;30(5):746–755.
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz M, Guerra-Vales JM, Francisco-Javier CF, et al. Fever of unknown origin in a patient with common variable immunodeficiency associated with multisystemic granulomatous disease. Intern Med. 2007;46(15):1197–1202.
   PubMed Web of Science ®Google Scholar
• Bethune C, Egner W, Garcez T, et al. British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non-infectious complications of common variable immunodeficiency disorders. Clin Exp Immunol. 2019 Jun;196(3):328–335.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Verma N, Lowe D, et al. British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders [Review]. J Allergy Clin Immunol Pract. 2017 Jul;5(4):938–945.
   PubMed Web of Science ®Google Scholar
• Smits B, Goldacker S, Seneviratne S, et al. The efficacy and safety of systemic corticosteroids as first line treatment for granulomatous lymphocytic interstitial lung disease. J Allergy Clin Immunol. 2022 Dec 29. Online ahead of print.
   Google Scholar
• Cereser L, De Carli R, Girometti R, et al. Efficacy of rituximab as a single-agent therapy for the treatment of granulomatous and lymphocytic interstitial lung disease in patients with common variable immunodeficiency. J Allergy Clin Immunol Pract. 2019 Mar;7(3):1055–1057.e2.
   PubMed Web of Science ®Google Scholar
• Bucciol G, Petrone A, Putti MC. Efficacy of mycophenolate on lung disease and autoimmunity in children with immunodeficiency. Pediatr Pulmonol. 2017 Oct;52(10):E73–e76.
   PubMed Web of Science ®Google Scholar
• Bintalib HM, Lowe DM, Mancuso G, et al. Corticosteroid-induced remission and mycophenolate maintenance therapy in granulomatous lymphocytic interstitial lung disease: long-term, longitudinal change in lung function in a single-centre cohort. ERJ Open Res. 2022 Oct;8(4):00024–2022.
   PubMedGoogle Scholar
• Lamers OAC, Smits BM, Leavis HL, et al. Treatment Strategies for GLILD in common variable immunodeficiency: a systematic review. Front Immunol. 2021;12:606099.
   PubMed Web of Science ®Google Scholar
• Warnatz K, Wehr C, Dräger R, et al. Expansion of CD19(hi)CD21(lo/neg) B cells in common variable immunodeficiency (CVID) patients with autoimmune cytopenia. Immunobiology. 2002 Dec;206(5):502–513.
   PubMed Web of Science ®Google Scholar
• Keller B, Strohmeier V, Harder I, et al. The expansion of human T-bet(high)cd21(low) B cells is T cell dependent. Sci Immunol. 2021 Oct 15;6(64):eabh0891.
   PubMed Web of Science ®Google Scholar
• Knight AK, Radigan L, Marron T, et al. High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency [Original]. ClinImmunol. 2007 Aug;124(2):182–189.
   Google Scholar
• Matson EM, Abyazi ML, Bell KA, et al. B cell dysregulation in common variable immunodeficiency interstitial lung disease. Front Immunol. 2020;11:622114.
   PubMed Web of Science ®Google Scholar
• Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis & Rheumatism. 2011 Dec;63(12):3918–3930.
   PubMed Web of Science ®Google Scholar
• Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell-targeting agents. Front Med. 2020;7:303.
   PubMedGoogle Scholar
• Boileau J, Mouillot G, Gérard L, et al. Autoimmunity in common variable immunodeficiency: correlation with lymphocyte phenotype in the French DEFI study. J Autoimmun. 2011 Feb;36(1):25–32.
   PubMed Web of Science ®Google Scholar
• Bateman EA, Ayers L, Sadler R, et al. T cell phenotypes in patients with common variable immunodeficiency disorders: associations with clinical phenotypes in comparison with other groups with recurrent infections. Clin Exp Immunol. 2012 Nov;170(2):202–211.
   PubMed Web of Science ®Google Scholar
• Taraldsrud E, Aukrust P, Jorgensen S, et al. Patterns of constitutively phosphorylated kinases in B cells are associated with disease severity in common variable immunodeficiency. Clin Immunol. 2017 Feb;175:69–74.
   PubMed Web of Science ®Google Scholar
• Walker LS, von Herrath M. CD4 T cell differentiation in type 1 diabetes. Clin Exp Immunol. 2016 Jan;183(1):16–29.
   PubMed Web of Science ®Google Scholar
• Krishnarajah S, Becher BT. (H) cells and cytokines in encephalitogenic disorders. Front Immunol. 2022;13:822919.
   PubMed Web of Science ®Google Scholar
• Szabo SJ, Sullivan BM, Stemmann C, et al. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science. 2002 Jan 11;295(5553):338–342.
   PubMed Web of Science ®Google Scholar
• Gadina M, Gazaniga N, Vian L, et al. Small molecules to the rescue: inhibition of cytokine signaling in immune-mediated diseases. J Autoimmun. 2017 Dec;85:20–31.
   PubMed Web of Science ®Google Scholar
• Fang D, Cui K, Cao Y, et al. Differential regulation of transcription factor T-bet induction during NK cell development and T helper-1 cell differentiation. Immunity. 2022 Apr 12;55(4):639–655.e7.
   PubMed Web of Science ®Google Scholar
• Bloomfield M, Kanderová V, Paračková Z, et al. Utility of ruxolitinib in a child with chronic mucocutaneous candidiasis caused by a novel STAT1 gain-of-function mutation. J Clin Immunol. 2018 Jul;38(5):589–601.
   PubMed Web of Science ®Google Scholar
• Forbes LR, Vogel TP, Cooper MA, et al. Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations. J Allergy Clin Immunol. 2018 Nov;142(5):1665–1669.
   PubMed Web of Science ®Google Scholar
• Vargas-Hernández A, Mace EM, Zimmerman O, et al. Ruxolitinib partially reverses functional natural killer cell deficiency in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. J Allergy Clin Immunol. 2018 Jun;141(6):2142–2155.e5.
   PubMed Web of Science ®Google Scholar
• Rao VK, Webster S, Dalm V, et al. Effective “activated PI3Kδ syndrome”-targeted therapy with the PI3Kδ inhibitor leniolisib. Blood. 2017 Nov 23;130(21):2307–2316.
   PubMed Web of Science ®Google Scholar
• Simonson WT, Markovina S, Grossman WJ, et al. Common variable immunodeficiency with regulatory T-cell deficiency treated with rapamycin. Annals of allergy, asthma & immunology: official publication of the American College of Allergy. Asthma, & Immunology. 2009 Feb;102(2):170–171.
   PubMed Web of Science ®Google Scholar
• Bride KL, Vincent T, Smith-Whitley K, et al. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17–28.
   PubMed Web of Science ®Google Scholar
• Azizi G, Abolhassani H, Yazdani R, et al. New therapeutic approach by sirolimus for enteropathy treatment in patients with LRBA deficiency. Eur Ann Allergy Clin Immunol. 2017 Sep;49(5):235–239.
   PubMed Web of Science ®Google Scholar
• Schwab C, Gabrysch A, Olbrich P, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J Allergy Clin Immunol. 2018 Dec;142(6):1932–1946.
   PubMed Web of Science ®Google Scholar
• Lee AY, Huynh N, Lin MW. Granulomatous skin lesions of common variable immunodeficiency treated with sirolimus. Australas J Dermatol. 2021 Aug;62(3):434–435.
   PubMed Web of Science ®Google Scholar
• Egg D, Rump IC, Mitsuiki N, et al. Therapeutic options for CTLA-4 insufficiency. J Allergy Clin Immunol. 2022 Feb;149(2):736–746.
   PubMed Web of Science ®Google Scholar
• Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis. Blood. 2019 Nov 21;134(21):1783–1786.
   PubMed Web of Science ®Google Scholar
• Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):161–170.
   PubMed Web of Science ®Google Scholar
• Rubín de Célix C, Chaparro M, Gisbert JP. Real-world evidence of the effectiveness and safety of ustekinumab for the treatment of crohn’s disease: systematic review and meta-analysis of observational studies. J Clin Med. 2022 Jul 20;11(14):4202.
   PubMed Web of Science ®Google Scholar
• Fevang B, Yndestad A, Sandberg WJ, et al. Low numbers of regulatory T cells in common variable immunodeficiency: association with chronic inflammation in vivo. Clin Exp Immunol. 2007 Mar;147(3):521–525.
   PubMed Web of Science ®Google Scholar
• Genre J, Errante PR, Kokron CM, et al. Reduced frequency of CD4(+)CD25(HIGH)FOXP3(+) cells and diminished FOXP3 expression in patients with Common Variable Immunodeficiency: a link to autoimmunity? Clin Immunol. 2009 Aug;132(2):215–221.
   PubMed Web of Science ®Google Scholar
• Yu GP, Chiang D, Song SJ, et al. Regulatory T cell dysfunction in subjects with common variable immunodeficiency complicated by autoimmune disease. Clin Immunol. 2009 May;131(2):240–253.
   PubMed Web of Science ®Google Scholar
• Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood. 2005 Jun 15;105(12):4743–4748.
   PubMed Web of Science ®Google Scholar
• Pilat N, Sprent J. Treg therapies revisited: tolerance beyond deletion. Front Immunol. 2020;11:622810.
   PubMed Web of Science ®Google Scholar
• Fraz MSA, Michelsen AE, Moe N, et al. Raised serum markers of t cell activation and exhaustion in granulomatous-lymphocytic interstitial lung disease in common variable immunodeficiency. J Clin Immunol. 2022 Jul;5:1–11.
   Google Scholar
• Aukrust P, Aandahl EM, Skålhegg BS, et al. Increased activation of protein kinase a type I contributes to the T cell deficiency in common variable immunodeficiency. J Immunol. 1999 Jan 15;162(2):1178–1185.
   PubMed Web of Science ®Google Scholar
• Cunningham-Rundles C, Bodian C, Ochs HD, et al. Long-term low-dose IL-2 enhances immune function in common variable immunodeficiency. Clin Immunol. 2001 Aug;100(2):181–190.
   PubMed Web of Science ®Google Scholar
• Perreau M, Vigano S, Bellanger F, et al. Exhaustion of bacteria-specific CD4 T cells and microbial translocation in common variable immunodeficiency disorders. J Exp Med. 2014 Sep 22;211(10):2033–2045.
   PubMed Web of Science ®Google Scholar
• Jørgensen SF, Trøseid M, Kummen M, et al. Altered gut microbiota profile in common variable immunodeficiency associates with levels of lipopolysaccharide and markers of systemic immune activation. Mucosal Immunol. 2016 Nov;9(6):1455–1465.
   PubMed Web of Science ®Google Scholar
• Shulzhenko N, Dong X, Vyshenska D, et al. CVID enteropathy is characterized by exceeding low mucosal IgA levels and interferon-driven inflammation possibly related to the presence of a pathobiont. Clin Immunol. 2018 Dec;197:139–153.
   PubMed Web of Science ®Google Scholar
• Fiedorová K, Radvanský M, Bosák J, et al. Bacterial but not fungal gut microbiota alterations are associated with Common Variable Immunodeficiency (CVID) Phenotype. Front Immunol. 2019;10:1914.
   PubMed Web of Science ®Google Scholar
• van Schewick CM, Nöltner C, Abel S, et al. Altered microbiota, impaired quality of life, malabsorption, infection, and inflammation in CVID patients with diarrhoea. Front Immunol. 2020;11:1654.
   PubMed Web of Science ®Google Scholar
• Bosák J, Lexa M, Fiedorová K, et al. Patients with Common Variable Immunodeficiency (CVID) show higher gut bacterial diversity and levels of low-abundance genes than the healthy housemates. Front Immunol. 2021;12:671239.
   PubMed Web of Science ®Google Scholar
• Jørgensen SF, Macpherson ME, Bjørnetrø T, et al. Rifaximin alters gut microbiota profile, but does not affect systemic inflammation - a randomized controlled trial in common variable immunodeficiency. Sci Rep. 2019 Jan 17;9(1):167.
   PubMedGoogle Scholar
• Troisi J, Venutolo G, Terracciano C, et al. The Therapeutic use of the Zonulin Inhibitor AT-1001 (Larazotide) for a Variety of Acute and Chronic Inflammatory Diseases. Curr Med Chem. 2021;28(28):5788–5807.
   PubMed Web of Science ®Google Scholar
• Hoilat GJ, Altowairqi AK, Ayas MF, et al. Larazotide acetate for treatment of celiac disease: a systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2022 Jan;46(1):101782.
   PubMed Web of Science ®Google Scholar
• Hurst JR, Warnatz K. Interstitial lung disease in primary immunodeficiency: towards a brighter future. Eur Respir J. 2020 Apr;55(4):2000089.
   PubMed Web of Science ®Google Scholar